Net Income (Loss) Attributable to Parent of Vitro Biopharma, Inc. from 31 Jul 2010 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Vitro Biopharma, Inc. quarterly and annual Net Income (Loss) Attributable to Parent in USD history and change rate from 31 Jul 2010 to 31 Oct 2025.
  • Vitro Biopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 31 Oct 2025 was $4,839,816, a 138% decline year-over-year.
  • Vitro Biopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 31 Oct 2025 was $10,851,802, a 9.9% decline year-over-year.
  • Vitro Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2025 was $10,851,802, a 9.9% decline from 2024.
  • Vitro Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was $9,873,560, a 84% decline from 2023.
  • Vitro Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was $5,356,717, a 22% increase from 2022.
Source SEC data
View on sec.gov
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Vitro Biopharma, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $10,851,802 $4,839,816 -$2,803,441 -138% 01 Aug 2025 31 Oct 2025 10-K 13 Feb 2026 2025 FY
Q2 2025 $8,048,361 $1,698,538 -$1,549,458 -1039% 01 May 2025 31 Jul 2025 10-Q 12 Sep 2025 2025 Q3
Q1 2025 $6,498,903 $1,478,786 +$1,640,133 +53% 01 Feb 2025 30 Apr 2025 10-Q 12 Sep 2025 2025 Q3
Q4 2024 $8,139,036 $2,834,662 +$1,734,524 +38% 01 Nov 2024 31 Jan 2025 10-Q 12 Sep 2025 2025 Q3
Q3 2024 $9,873,560 $2,036,375 -$156,167 -8.3% 01 Aug 2024 31 Oct 2024 10-K 13 Feb 2026 2025 FY
Q2 2024 $9,717,393 $149,080 +$722,604 +83% 01 May 2024 31 Jul 2024 10-Q 12 Sep 2025 2025 Q3
Q1 2024 $10,439,997 $3,118,919 -$1,704,219 -120% 01 Feb 2024 30 Apr 2024 10-Q 12 Sep 2025 2025 Q3
Q4 2023 $8,735,778 $4,569,186 -$3,379,061 -284% 01 Nov 2023 31 Jan 2024 10-Q 12 Sep 2025 2025 Q3
Q3 2023 $5,356,717 $1,880,208 +$556,728 +23% 01 Aug 2023 31 Oct 2023 10-K 28 Jan 2025 2024 FY
Q2 2023 $5,913,445 $871,684 +$1,854,307 +68% 01 May 2023 31 Jul 2023 10-Q 16 Sep 2024 2024 Q3
Q1 2023 $7,767,752 $1,414,700 -$79,310 -5.9% 01 Feb 2023 30 Apr 2023 10-Q 16 Sep 2024 2024 Q3
Q4 2022 $7,688,442 $1,190,125 -$828,393 -229% 01 Nov 2022 31 Jan 2023 10-Q 16 Sep 2024 2024 Q3
Q3 2022 $6,860,049 $2,436,936 01 Aug 2022 31 Oct 2022 10-K 29 Jan 2024 2023 FY
Q2 2022 $2,725,991 01 May 2022 31 Jul 2022 10-Q 28 Aug 2023 2023 Q3
Q1 2022 $1,335,390 01 Feb 2022 30 Apr 2022 10-Q 28 Aug 2023 2023 Q3
Q4 2021 $361,732 01 Nov 2021 31 Jan 2022 10-Q 28 Aug 2023 2023 Q3
Q1 2015 $251,804 $75,393 -$11,315 -18% 01 Feb 2015 30 Apr 2015 10-Q 22 Jan 2016 2015 Q2
Q4 2014 $240,489 $48,870 +$6,038 +11% 01 Nov 2014 31 Jan 2015 10-Q 24 Mar 2015 2015 Q1
Q3 2014 $246,527 $83,134 01 Aug 2014 31 Oct 2014 10-K 22 Sep 2016 2015 FY
Q2 2014 $44,407 +$3,998 +8.3% 01 May 2014 31 Jul 2014 10-Q 22 Sep 2014 2014 Q3
Q1 2014 $64,078 01 Feb 2014 30 Apr 2014 10-Q 22 Jan 2016 2015 Q2
Q4 2013 $54,908 -$16,198 -42% 01 Nov 2013 31 Jan 2014 10-Q 24 Mar 2015 2015 Q1
Q2 2013 $48,405 +$2,997 +5.8% 01 May 2013 31 Jul 2013 10-Q 22 Sep 2014 2014 Q3
Q4 2012 $203,941 $38,710 +$23,716 +38% 01 Nov 2012 31 Jan 2013 10-Q 21 Mar 2013 2013 Q1
Q3 2012 $227,657 $38,559 +$12,266 +24% 01 Aug 2012 31 Oct 2012 10-K 12 Feb 2014 2013 FY
Q2 2012 $239,923 $51,402 +$6,685 +12% 01 May 2012 31 Jul 2012 10-Q/A 17 Oct 2012 2012 Q3
Q1 2012 $246,608 $75,270 -$210,267 -156% 01 Feb 2012 30 Apr 2012 10-Q/A 22 Jun 2012 2012 Q2
Q4 2011 $36,341 $62,426 -$22,319 -56% 01 Nov 2011 31 Jan 2012 10-Q 21 Mar 2013 2013 Q1
Q3 2011 $14,022 $50,825 01 Aug 2011 31 Oct 2011 10-K 12 Feb 2013 2012 FY
Q2 2011 $58,087 -$18,629 -47% 01 May 2011 31 Jul 2011 10-Q/A 17 Oct 2012 2012 Q3
Q1 2011 $134,997 01 Feb 2011 30 Apr 2011 10-Q/A 22 Jun 2012 2012 Q2
Q4 2010 $40,107 01 Nov 2010 31 Jan 2011 10-Q 21 Mar 2012 2012 Q1
Q2 2010 $39,458 01 May 2010 31 Jul 2010 10-Q/A 12 Oct 2011 2011 Q3

Vitro Biopharma, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $10,851,802 -$978,242 -9.9% 01 Nov 2024 31 Oct 2025 10-K 13 Feb 2026 2025 FY
2024 $9,873,560 -$4,516,843 -84% 01 Nov 2023 31 Oct 2024 10-K 13 Feb 2026 2025 FY
2023 $5,356,717 +$1,503,332 +22% 01 Nov 2022 31 Oct 2023 10-K 28 Jan 2025 2024 FY
2022 $6,860,049 01 Nov 2021 31 Oct 2022 10-K 29 Jan 2024 2023 FY
2015 $245,865 +$662 +0.27% 01 Nov 2014 31 Oct 2015 10-K 22 Sep 2016 2015 FY
2014 $246,527 $0 0% 01 Nov 2013 31 Oct 2014 10-K 22 Sep 2016 2015 FY
2013 $246,527 -$18,870 -8.3% 01 Nov 2012 31 Oct 2013 10-Q 22 Jan 2016 2015 Q2
2012 $227,657 -$213,635 -1524% 01 Nov 2011 31 Oct 2012 10-K 12 Feb 2014 2013 FY
2011 $14,022 +$243,110 +95% 01 Nov 2010 31 Oct 2011 10-K 12 Feb 2013 2012 FY
2010 $257,132 01 Nov 2009 31 Oct 2010 10-K/A 16 Feb 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.